Ryan Nelson, PharmD, discusses the STRIPE Annual Meeting and Consensus Workshop’s focus on unifying pharmacogenetic guidelines across major organizations, such as the FDA, European Medicines Agency, Clinical Pharmacogenetics Implementation Consortium, and National Comprehensive Cancer Network.
Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency.
Panelists discuss how recent phase 3 trial data from PERSEUS, IsKia, and GMMG HD7 are shaping their approach to induction and consolidation therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, particularly focusing on the incorporation of CD38 antibodies into upfront treatment regimens and the potential shift from triplet to quadruplet therapies based on these pivotal trial findings.
Carrie Koenigsfeld, PharmD, FAPhA, discusses her experience with concerns and perceptions contributing to RSV vaccine hesitancy among older adults, such as safety, efficacy, necessity, awareness, and cost, and she explores how pharmacists can effectively counsel patients and caregivers about RSV vaccines while tailoring communication strategies to educate older adults with low health literacy.
Damage to a Baxter manufacturing plant in the aftermath of Hurricane Helene has led to significant IV fluid shortages throughout the country.
Stephanie White, PharmD, CSP, is presenting at the NCODA Fall Summit in Orlando, Florida.
Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.
Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.
Pharmacists are positioned to combat the opioid crisis through educating the public and advocating for policy changes to enable harm reduction strategies.
Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings
Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Two MUSC pharmacy technicians discuss how techs are pivotal in pharmacy, whether in the community or clinical setting, and how it is important to maintain high standard of care in a changing environment.
Simply stating a team member good job, whether it be within a group or in a 1-on-1 setting, 2 MUSC pharmacy technicians emphasize that recognition and encouragement go a long way.
Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.
Ilianette Miranda, RPh discusses her career-long efforts to integrate pharmacists into the health care system in Puerto Rico.
In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.
The president and CEO of Employers' Forum of Indiana says the pharmacists must be involved and engaged with employers to improve outcomes in health care.
This Women Pharmacists Day, Jolynn Sessions, PharmD, BCOP, FHOPA, discussed the crucial role of women in pharmacy.
Terry Keys highlights the role of language and terminology as barriers for patients receiving cancer care.
Amelia Arnold, PharmD, reflects on the growing recognition of pharmacists as valuable clinical providers.
Pharmacists also help patients manage their adverse effects and treat patients to live healthy lives.
Sarah Hudson-Disalle, PharmD, highlights the significant impact of EHR automation on biosimilar access and costs.
Nadine Barrett, PhD, MA, MPH, discusses the role of international collaborations to advance global cancer care access.
Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the CDC’s recommendation for an RSV vaccine for all adults aged 75 years and older, as well as those aged 60 to 74 years at increased risk, and outlines the conditions that elevate the risk for severe illness, including the implications of severe illness, such as hospitalization, long-term effects, complications, comorbidities, and mortality, while also comparing how RSV infection affects older vs younger adults.
Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.
Naoto T. Ueno, MD, PhD, FACP, discussed the role of the Hawaiʻi Cancer Consortium to advance trial and treatment efforts for patients with cancer.
Courtney VanHouzen, PharmD shares insights about the community bispecific program at Munson Healthcare.
Shirish Gadgeel, MD, discusses the promising results of the randomized phase 3 HARMONi-2/AK112-303 study comparing ivonescimab to pembrolizumab in PD-L1–positive advanced non-small cell lung cancer.
